News & Updates
Excerpt from the Press Release: BOSTON, Oct. 20, 2022 /PRNewswire/ — IBSA Group and Granata Bio today announced the screening of the first patient in the pivotal phase III PROGRESS (PROGesterone fRozen Euploid blaStocyst tranSfer) clinical trial (Clinical Trials.gov Identifier: NCT04549116). The PROGRESS study is a multicenter, randomized, controlled, double-blind, double-dummy study to evaluate the safety…
Read More
Excerpt from the Press Release: 2023 Ideation Key Program The Challenge: Develop An Idea Build A Prototype Pitch Your Idea Mission: Move a healthcare problem from idea to a demonstrable, prototype with commercial potential, that aims to improve the lives of those living with chronic conditions. Objective: Develop early-stage, validated and tested ideas to save…
Read More
Excerpt from the Press Release: CAMBRIDGE, Mass., ROTTERDAM and SUZHOU, China, Oct. 20, 2022 /PRNewswire/ — Harbour BioMed (“HBM”, HKEX: 02142) announced that, it has successfully completed the dosing of first patient in the global phase I trial of B7H4x4-1BB bispecific antibody HBM7008 in the United States. This study will evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics,…
Read More
Excerpt from the Press Release: Medtronic (NYSE:MDT) revealed its plans for an incubation and acceleration platform for innovation in the neurovascular space. In a presentation yesterday at DeviceTalks West in Santa Clara, California, the company unveiled its plan to bring innovations to market to address strokes. Daniel Volz, president of Medtronic Neurovascular, and Derek Crittenden,…
Read More
Australia now open for study of rare, rapidly progressive Parkinsonian Disorder Excerpt from the Press Release: MELBOURNE, Australia and SAN FRANCISCO, Oct. 13, 2022 /PRNewswire/ — Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that it has received approval in Australia from…
Read More
Excerpt from the Press Release: SAN DIEGO, Oct. 14, 2022 /PRNewswire/ — Phanes Therapeutics, Inc. (Phanes), a clinical stage biotech company focused on oncology, announced today that it has received clearance from the US Food and Drug Administration (FDA) to commence Phase I studies with PT217, its anti-Delta-like ligand 3 (DLL3)/anti-Cluster of differentiation 47 (CD47)…
Read More
Partnership brings Iterative Scopes’ AI Recruitment technology to One GI® Excerpt from the Press Release: CAMBRIDGE, Mass.–(BUSINESS WIRE)–Iterative Scopes, a pioneer in precision-medicine technologies for gastroenterology, announced today that it has partnered with One GI®, a gastroenterology management services organization (MSO), to bring its AI Recruitment (AIR) technology to One GI’s clinical research. Initially, One…
Read More
Plans for the round include investing in R&D for its tech platform and hiring across all teams. The news follows the company’s recent move to a new Center City office. Excerpt from the Press Release: Following a $20 million Series B round last year, NeuroFlow just closed a $25 million round of financing to continue…
Read More
Topline results for PATHFNDR-1 study expected in Q3 2023 Excerpt from the Press Release: SAN DIEGO, Oct. 13, 2022 (GLOBE NEWSWIRE) — Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced the completion of enrollment in the Phase 3 PATHFNDR-1 study. PATHFNDR-1 is one of two ongoing, placebo-controlled Phase 3 studies evaluating the safety and efficacy of…
Read More
Next Generation Senza® HFX iQ™ is the First and Only SCS System that Uses Artificial Intelligence to Optimize and Maintain Pain Relief Using Each Patient’s Response Excerpt from the Press Release: REDWOOD CITY, Calif., Oct. 12, 2022 /PRNewswire/ — Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the…
Read MoreRequest Your Demo Today!
From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?